In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amylin and Takeda partner for obesity compounds; deal ends

Executive Summary

Amylin Pharmaceuticals and Takeda will work together on the development and commercialization of Amylin's Phase II pramlintide/metreleptin and davalintide obesity therapies. The deal also includes additional obesity compounds from each company's pipeline--a Y family hormone of Amylin's and an undisclosed preclinical candidate from Takeda--as well as follow-on products for indications including but not limited to glycemic control and cardiovascular disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies